Raymond James raised the firm’s price target on Revvity (RVTY) to $146 from $144 and keeps an Outperform rating on the shares. Revvity had an “adequate” Q3, which saw in line revenues on lighter Life Sciences and stronger Diagnostics, with adjusted EPS coming in 14% ahead primarily on below the line benefits, the analyst tells investors in a research note. China remains a key headwind, with the impact of stimulus likely needed to drive a material inflection but unlikely to appear in Q4, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RVTY:
- Revvity price target raised to $144 from $141 at TD Cowen
- Revvity price target lowered to $145 from $150 at Bernstein
- Revvity price target raised to $138 from $136 at Baird
- Revvity Reports Strong Q3 Growth and New Share Buyback
- Morning Movers: Air Transport Services jumps following $3.1B take-private deal
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
